MSN Pushes for Rehearing on Revival of Novartis' Entresto Patent
MSN Laboratories Pvt. Ltd. urged the Federal Circuit to reconsider a three-judge panel’s January ruling that revived a patent for Novartis AG’s blockbuster heart-disease drug Entresto.
news.bloomberglaw10d
Novartis Flags Legal Gap as MSN Eyes Generic Entresto Launch
Latest fight in web of litigation centers on brief window MSN says expired patent can’t justify delayed FDA approval MSN Laboratories Pvt. Ltd. is pushing to launch its generic Entresto during a brief ...
Hosted on MSN17d
Core Laboratories Q4 2024 Earnings Preview
Core Laboratories (NYSE:CLB) is scheduled to announce Q4 earnings results on Wednesday, January 29th, after market close.The consensus EPS Estimate is $0.21 (+10.5% Y/Y) and the consensus Revenue ...
Hosted on MSN23d
Abbott Laboratories slips after Q4 topline miss
Abbott Laboratories (NYSE:ABT) traded ~2% lower in the premarket on Wednesday after the diagnostics company's Q4 2024 results fell short of Street forecasts for revenue despite outperformance in ...